These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21910132)

  • 21. Cytotoxic and peptidase inhibitory activities of selected non-hepatotoxic cyclic peptides from cyanobacteria.
    Bubik A; Sedmak B; Novinec M; Lenarcic B; Lah TT
    Biol Chem; 2008 Oct; 389(10):1339-46. PubMed ID: 18713022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploitation of marine algae: biogenic compounds for potential antifouling applications.
    Bhadury P; Wright PC
    Planta; 2004 Aug; 219(4):561-78. PubMed ID: 15221382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cyanobacterial origin of potent anticancer agents originally isolated from sea hares.
    Luesch H; Harrigan GG; Goetz G; Horgen FD
    Curr Med Chem; 2002 Oct; 9(20):1791-806. PubMed ID: 12369878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural products from marine organisms and their associated microbes.
    König GM; Kehraus S; Seibert SF; Abdel-Lateff A; Müller D
    Chembiochem; 2006 Feb; 7(2):229-38. PubMed ID: 16247831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologically active secondary metabolites from marine cyanobacteria.
    Nunnery JK; Mevers E; Gerwick WH
    Curr Opin Biotechnol; 2010 Dec; 21(6):787-93. PubMed ID: 21030245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicological effects of cyanobacterial metabolites on zebrafish larval development.
    Jacinavicius FR; Geraldes V; Fernandes K; Crnkovic CM; Gama WA; Pinto E
    Harmful Algae; 2023 Jun; 125():102430. PubMed ID: 37220983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developments of Cyanobacteria for Nano-Marine Drugs: Relevance of Nanoformulations in Cancer Therapies.
    Bajpai VK; Shukla S; Kang SM; Hwang SK; Song X; Huh YS; Han YK
    Mar Drugs; 2018 May; 16(6):. PubMed ID: 29882898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbial degradation of cyanobacterial cyclic peptides.
    Kato H; Imanishi SY; Tsuji K; Harada K
    Water Res; 2007 Apr; 41(8):1754-62. PubMed ID: 17307215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural antifoulants from the marine cyanobacterium Lyngbya majuscula.
    Tan LT; Goh BP; Tripathi A; Lim MG; Dickinson GH; Lee SS; Teo SL
    Biofouling; 2010 Aug; 26(6):685-95. PubMed ID: 20658384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides.
    Matthew S; Ross C; Rocca JR; Paul VJ; Luesch H
    J Nat Prod; 2007 Jan; 70(1):124-7. PubMed ID: 17253864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marine pharmacology in 1999: antitumor and cytotoxic compounds.
    Mayer AM; Lehmann VK
    Anticancer Res; 2001; 21(4A):2489-500. PubMed ID: 11724312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of inhibitors of daphnid trypsin in the widely distributed cyanobacterial genus Planktothrix.
    Rohrlack T; Christoffersen K; Friberg-Jensen U
    Environ Microbiol; 2005 Oct; 7(10):1667-9. PubMed ID: 16156739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyanobacterial protease inhibitor microviridin J causes a lethal molting disruption in Daphnia pulicaria.
    Rohrlack T; Christoffersen K; Kaebernick M; Neilan BA
    Appl Environ Microbiol; 2004 Aug; 70(8):5047-50. PubMed ID: 15294849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuro-apoptogenic and blood platelet targeting toxins in benthic marine cyanobacteria from the Portuguese coast.
    Selheim F; Herfindal L; Martins R; Vasconcelos V; Døskeland SO
    Aquat Toxicol; 2005 Sep; 74(4):294-306. PubMed ID: 16039729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasion of toxic marine cyanobacteria in to the tsunami affected coastal villages of southern India.
    Muthukumaravel S; Padmanabhan V; Boopathidoss PS; Sadanandane C; Srinivasan R; Gunasekaran K; Sabesan S; Balaraman K
    J Commun Dis; 2010 Jun; 42(2):135-8. PubMed ID: 22471172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the study of mechanism of action of marine neurotoxins.
    Narahashi T; Roy ML; Ginsburg KS
    Neurotoxicology; 1994; 15(3):545-54. PubMed ID: 7854588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phycochemistry and bioactivity of cyanobacterial secondary metabolites.
    Srivastava R; Prajapati R; Kanda T; Yadav S; Singh N; Yadav S; Mishra R; Atri N
    Mol Biol Rep; 2022 Nov; 49(11):11149-11167. PubMed ID: 36161579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actin-binding marine macrolides: total synthesis and biological importance.
    Yeung KS; Paterson I
    Angew Chem Int Ed Engl; 2002 Dec; 41(24):4632-53. PubMed ID: 12481316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-occurrence of beta-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990-2004.
    Metcalf JS; Banack SA; Lindsay J; Morrison LF; Cox PA; Codd GA
    Environ Microbiol; 2008 Mar; 10(3):702-8. PubMed ID: 18237305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.